History Sharkliveroil l What is squalene? l The Role of Squalene in Health l Dr. Carl A. Luer
Dr. William Lane interview by dr. Passwater l Dr. William Lane l Dr. Bikul Das l G.S. Kelly Clinical uses
History of Shark liver oil
History Of Shark Liver Oil
Fisherman of the Surga Bay on the Izu Peninsula of ancient Japan called it "Samedawa" or "cure all". The sharks they fished from the bottom of the bay measuring over 1000 meters deep, had a delectable meat. They specially valued its liver oil which they ingested regularly because they felt better whenever they took it.
In 1758, Swedish botanist Carolus Linnaeus discovered and claimed the great health and medicinal value of oil extracts from deep sea sharks such as the spiny dogfish. In the Micronesian Islands, a "miracle working" shark oil has been an age old remedy for various sickness and diseases as well as a familiar source of strength, stamina and virility. The historic health benefits of shark liver oil has always been a mainstay in Scandinavian folk medicine.
In Norway and Sweden, shark liver oil was used traditionally by fishermen for healing wounds and irritations of the respiratory tract and alimentary canal. In China, the extract of deep sea shark has been recorded in the ancient pharmaceutical book "Honzukomuko".
In Spain, ancient mariners regularly took "aceite de bacalao" or oil of the great fish. They claimed a greater resistance to colds and various other diseases because of it. Even in Ernest Hemingway's book, "The Old Man and the Sea" it says of the old man... "He also drank shark liver oil each day from the drum in the shack where many of the fishermen kept their gear....It was very good against all colds and grippes and it was good for the eyes."
In 1906, Dr. Mitsumaru Tsujimoto made an in depth research on shark liver oil, specifically that of the deep sea shark species; the "Squalidae Group", and discovered that an extremely great quantity of unsaturated hydrocarbons was contained in the liver oil of these deep sea sharks. He later called the oil "Squalene". Dr. Tsujimoto's brilliant discovery was not fully established until 1931 when Prof. Calour, a Nobel prize awardee at Zurich University, Switzerland certified that squalene shark liver oil is a lipoprotein, an unsaturated hydrocarbon with a chemical structure C30H50. This means simply that it mainly contains 30 carbon atoms and 50 hydrogen atoms. Dr. Calour in his study of the chemical behavior of this unsaturated hydrocarbon revealed that the compound is naturally lacking 12 hydrogen atoms in its original form for it to be stable (the stable compound is C30H62) and will "capture hydrogen atoms" from any source available to make it stable and saturated. The most abundant source of hydrogen is water ­p; H20. (Our food contains much H20, body fluids and blood are mainly H20, body cells contain much water, the human body is actually 70% water). Theoretically, C30H50 (squalene) reacts with water (H20) this way: C30H50 + 6H20 ­p; C30H62 + 302. By capturing the hydrogen molecules, 3 oxygen molecules from the water are released. This shows that squalene, through a natural reaction with water, is capable of providing oxygen essential for healthy metabolism. This basic scientific theory shown in the above formula should provide us an insight how squalene might work when present in our bodies.
Amazing discoveries continue to be made on shark liver oil. More careful scientific studies are being made to thoroughly examine its full composition and health benefits. In 1922, scientists isolated the therapeutically active component in shark liver oil called alkoxyglycerols.
Since the 1950's, this component has been studied clinically for its healing benefits in over 50 countries. Alkoxyglycerols (AKG's) in mothers milk, is the key substance which provides infants with natural protection and immunity against infection as it helps in the continued development of their immune system. There are 10 times more AKG's in mother's milk than in cow's milk. Science has proven that breast fed babies are more resistant to infection and diseases even all through life because of the more abundant ingestion of AKG's in their early physical development. This immune supportive nutrient, Alkoxyglycerols (AKG's) is the primary active component in shark liver oil. In fact, there are 1000 times more AKG's in shark liver oil than mother's milk. and human adults commensurately need 1000 times more AKG's than infants in the need for continuing boosting and enhancing ones immune system.
In the 1990's Johns Hopkins University discovered another ingredient in shark liver oil, Squalamine, found to be effective against many yeast, fungus and bacterial infections, and especially offers promise to immune compromise persons such as AIDS and cancer patients. Shark liver oil may well contain the secret of improved health and longevity for mankind.
Historical importance
Sharks and their relatives, the skates and rays, have enjoyed tremendous success during their nearly 400 million years of existence on earth. One reason for this certainly is their uncanny ability to resist disease. Sharks do get sick, but their incidence of disease is much lower than among the other fishes. While statistics are not available on most diseases in fishes, reptiles, amphibians, and invertebrates, tumor incidence in these animals is carefully monitored by the Smithsonian Institution in Washington, D.C.
The Smithsonian's enormous database, called the Registry of Tumors in Lower Animals, catalogs tissues suspected of being tumorous, including cancers, from all possible sources throughout the world. Of the thousands of tissues in the Registry, most of them are from fish but only a handful (fewer than 25) are from sharks or rays. Most of these are classified as fibrous responses to wounds, parasites, or goiters (enlarged thyroid glands sometimes developed by sharks in captivity), leaving only 8 to 10 legitimate tumors among all the shark and ray tissues examined.
This low incidence of tumors among the sharks and their relatives has prompted biochemists and immunologists at Mote Marine Laboratory (MML) to explore the mechanisms that may explain the unusual disease resistance of these animals. To do this, we have established the nurse shark and clearnose skate as laboratory animals. These sharks and skates are maintained at MML under controlled conditions and utilized in much the same way that mice, rats, guinea pigs, and rabbits are used in more conventional biomedical research.
Initially, we designed experiments to see whether tumors could be induced in the sharks and skates by exposing them to potent carcinogenic (cancer-causing) chemicals. This was done by placing the chemicals in their food or surrounding tank water, or by direct injection into their muscle. Then, we monitored subsequent pathways of metabolism or detoxification of the carcinogens in the test animals. While there were similarities and differences in the responses when compared with mammals, no changes in the target tissues or their genetic material ever resulted in cancerous tumor formation in the sharks or skates.
The chemical exposure studies, encompassing about ten years of research effort, have led us to more recent investigations of the shark immune system. As with mammals, including humans, the immune system of sharks probably plays a vital role in the overall health of these animals. But there are some important differences between the immune arsenals of mammals and sharks. The immune system of mammals typically consists of two parts which utilize a variety of immune cells as well as several classes of proteins called immunoglobulins (antibodies).
Compared to the mammalian system, which is quite specialized, the shark immune system appears primitive but remarkably effective. Sharks apparently possess immune cells with the same functions as those of mammals, but the shark cells appear to be produced and stimulated differently. Furthermore, in contrast to the variety of immunoglobulins produced in the mammalian immune system, sharks have only one class of immunoglobulin (termed IgM). This Immunoglobulin normally circulates in shark blood at very high levels and appears to be ready to attack invading substances at all times.
Another difference lies in the fact that sharks, skates, and rays lack a bony skeleton, and so do not have bone marrow. In mammals, immune cells are produced and mature in the bone marrow and other sites, and, after a brief lag time, these cells are mobilized to the bloodstream to fight invading substances. In sharks, the immune cells are produced in the spleen, thymus and unique tissues associated with the gonads (epigonal organ) and esophagus (Leydig organ). Some maturation of these immune cells occurs at the sites of cell production, as with mammals. But our studies at MML in collaboration with researchers at Clemson University have determined that a significant number of immune cells in these animals actually mature as they circulate in the bloodstream. Like the ever-present IgM molecule, immune cells already in the shark's blood may be available to respond without a lag period, resulting in a more efficient immune response.
Our future plans include further investigations of the differences between mammals and sharks in the regulation of immune cells. Since some new approaches to cancer therapy involve the stimulation of immune cell production, an understanding of the control of proliferating immune cells in the circulating blood of sharks would be valuable. This information may someday lead to improved methods of immune cell regulation in humans, especially cancer patients.
But human health applications from our research are many years in the future, and will rely on continued funding and active collaboration with the drug industry and medical community. Meanwhile, there are many public misconceptions about the clinical potential of shark-derived products for treatment of disease. For example, freeze-dried shark cartilage pills, marketed as food supplements through health food stores and mail order houses, are being touted as miracle cures for cancer as well as arthritis.
The claims are based on research conducted during the 1980's at the Massachusetts Institute of Technology (MIT) and at Mote Marine Laboratory. These studies of cow and shark cartilage were designed to understand how cartilage is naturally able to resist penetration by blood capillaries. If the basis for this inhibition could be identified, it was reasoned, then it might lead to the development of a new drug therapy. Such a drug could control the spread of blood vessels feeding a cancerous tumor, or the inflammation associated with arthritis.
The research showed that only very small amounts of active material, with limited ability to control blood vessel growth, can be obtained from large amounts of raw cartilage. The cartilage must be subjected to several weeks of harsh chemical procedures to extract and concentrate the active ingredients. Once this is done, the resulting material is able to inhibit blood vessel growth in laboratory tests on animal models, when the concentrated extract is directly applied near the growing blood vessels.
Unfortunately, there is no logical reason to conclude that freeze-dried shark cartilage pills taken orally could "seek out" a malignant tumor in a cancer patient and inhibit the blood vessels feeding it in a manner similar to the laboratory tests. Also, there is no reason to think that shark cartilage contains anything which is not found in other animal cartilage. But there is so much more cartilage in sharks, since they have an all-cartilaginous skeleton, that they have served as sources for this material.
Finally, since the limited amount of active material used in the laboratory test must be chemically extracted, there is no reason to assume that this material is released passively from cartilage when still in the animal to inhibit blood vessel growth elsewhere in the body. This means that cartilage, no matter whether in a shark, a cow, a dog, or a human, probably plays no active role in disease resistance in the living animal. The statements made by shark cartilage pill promoters that it is cartilage that gives sharks their immunity to cancer, then, are inaccurate and irresponsible.
This is not to say that the basic research to understand the chemical basis for cartilage resistance to blood vessels shouldn't continue. The potential for this research to lead to new drug therapies is very real. But what should be halted is the use of sharks as a source of cartilage to be ground up and marketed as a panacea, with little or no support for effective results in fighting disease when taken as a food supplement. We owe it to the sharks, but more importantly to the suffering cancer patients, to provide a sound basis for such actions. At this point, no such justification exists.
| Dr. Carl Luer is the Biomedical Program Manager at Mote Marine Laboratory. Dr. Luer's biomedical research uses sharks and skates as laboratory animals models to investigate mechanisms of cancer inhibition and cellular immune function. His studies also include the reproductive biology and embryology of the clearnose skate. Dr. Luer is a member of the Board of Directors of the American Elasmobranch Society. |
Sources and references Squalene and haaienleverolie
1. Berger S.M.: 'Forever Young', 1ste ed., 1989.
2. Tsjujimoto M., Toyam Y., 1992: ' Unsaponifiable Constituents (higher alcohol) of the liver oil of the sharks and rays'. Chem Umschau 29: 27 - 29, 43 - 45
3. Dr. Conrado O. Venzon, 'The Precious Oil of the Deep-Sea Shark', Worldwide Publ.Services Quezon City, Philippines.
4. 'The Healer Shark', Neil Solomons MD.Ph.D. and Richard Passwater, Ph.D. 1998
5. Brohult, Astrid, 1963: 'Alkylglycerols and their use in Radiation Treatment', Acta. Radiol. Suppl. 223: 7 - 99, Stockholm.
6. Dr. William Lane Comac, 'Sharks don't Get Cancer', 1992.
7. ' Fish Oil May Ease Arthritis Pain'. Med. World News July 14, 1986, p. 9.
8 Glausinz: 'The Secret Healing Power of Sharks', The Medicine Discoverer Magazine, January 1994.
9. Prof. dr. J. de Vries, Hart- en vaatziekten vormen samen met kanker de belangrijkste doodsoorzaak in de westerse wereld. Studies wijzen uit dat visolie unieke vetzuren bevat die preventief werken. Waar blijven de aanbevelingen van volksgezondheid? Natuur en techniek 65, 12 1997
10. Kromhout, Daan, Bosschieter, Edward B. and Coulander, Cor de Lezenne, 1985: 'The Inverse relationship Between Fish Oil Consumption and 20-Year old Mortality from Coronary Health Diseases'.
11. Takashi Yokota M.D., 'The Miracle of Squalene (Cures Cancer & Modern Diseases)'
The Medicine Discoverer, January 1994, 'The Secret Healing Power of Sharks'.
13. Martin-Moreno JM, Willett WC, Gorgojo L et al. Dietary fat, olive oil intake and breast cancer risk. Int.J Cancer 1994;58:
14. Trichopoulou A, Katsouyanni K, Stuver S et al. Consumption of olive oil and specific food groups in relation to breast cancer risk in Greece. J Natl.Cancer Inst. 1995;87:110-6.
15. Landa MC, Frago N, Tres A. Diet and the risk of breast cancer in Spain. Eur.J Cancer Prev. 1994;3:313-20.
16. Franceschi S, Favero A, Decarli A et al. Intake of macronutrients and risk of breast cancer. Lancet 1996;347:1351-6.
17. La Vecchia C, Negri E. Fats in seasoning and the relationship to pancreatic cancer. Eur.J Cancer Prev. 1997;6:370-3.
18. Porter, Ph.D. Squalene Monooxygenase, University of Kentucky
21. Nakagawa M, Yamaguchi T, Fukawa H, et al. Potentiation by squalene of the cytotoxicity of anticancer agents against culture mammalian cells and murine tumor. Jpn J Cancer Res 1985;76:315-320.
22. Asnis DS, Saltzman HP, Melchert A. Shark oil pneumonia. An overlooked entity. Chest 1993;103:976-977.
24. Smith TJ, Yang GY, Seril DN, Liao J, Kim S. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis by dietary olive oil and squaleen. Carcinogenesis 1998;19:703-6.
25. Smith, T. J., Kim, S., Lee, M. J., Yang, G. Y., Newmark, H. L., and Yang, C. S. Inhibition of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NKK)-induced lung tumorigenesis and DNA oxidation by dietary squaleen. Proceedings of the American Association for Cancer Research 40, 262. 1999. Ref Type: Journal (Full)
26. Dr. Bikul Das. The Science behind Squalene. The Human Antioxidant. 2000. Toronto Canada
27. Kelly GS. Squaleen and its potential clinical uses. Altern.Med Rev. 1999;4:29-36.
28. Fliesler SJ, Keller RK. Isoprenoid metabolism in the vertebrate retina. Int.J Biochem.Cell Biol. 1997;29:877-94.
29. Strandberg TE, Tilvis RS, Miettinen TA. Metabolic variables of cholesterol during squaleen feeding in humans: comparison with cholestyramine treatment. J Lipid Res. 1990;31:1637-43.
30. Kohno Y, Egawa Y, Itoh S, Nagaoka S, Takahashi M, Mukai K. Kinetic study of quenching reaction of singlet oxygen and scavenging reaction of free radical by squaleen in n-butanol. Biochim.Biophys.Acta 1995;1256:52-6.
31. Miettinen TA, Vanhanen H. Serum concentration and metabolism of cholesterol during rapeseed oil and squaleen feeding. Am J Clin.Nutr. 1994;59:356-63.
32. Chan P, Tomlinson B, Lee CB, Lee YS. Effectiveness and safety of low-dose pravastatin and squaleen, alone and in combination, in elderly patients with hypercholesterolemia. J Clin.Pharmacol. 1996;36:422-7.
33. Smith TJ. Squaleen: Potential chemopreventive agent by squalene. Expert.Opin.Investig.Drugs 2000;9:1841-8.
34. Martin-Moreno JM, Willett WC, Gorgojo L et al. Dietary fat, olive oil intake and breast cancer risk. Int.J Cancer 1994;58:
35.
Luer, C. A. et al: (In
Vitro Metabolism Of The Proximate Carcinogen Aflatoxin-B 1 By Liver Portions
Of The Calf, Nurse Shark And Clearnose Skate) Fed. Froc. 46:2 290, 1987
36.
Trichopoulou A, Katsouyanni K, Stuver S et al. Consumption of olive oil and
specific food groups in relation to breast cancer risk in Greece. J
Natl.Cancer Inst. 1995;87:110-6.
37. Paul Terry, Paul Lichtenstein, Maria Feychting, Anders Ahlbom, Alicja Wolk, Vol 357, June 2, 2001 The Lancet
38. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors a and g
. Steven A. Kliewer, Scott Sundseth et al. Nat. Academy of Sciences of the USA 199739. Joseph Vamecq, Norbert Latruffe, Vol 354, July 10, 1999 The Lancet
40. E. Mueller, P. Sarraf , …… Bruce M. Spiegelman. Molecular Cell. Vol 1, 465-470, February, 1998
